989 results on '"Muzikansky, Alona"'
Search Results
2. Real-time monitoring of mitochondrial oxygenation during machine perfusion using resonance Raman spectroscopy predicts organ function
3. Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2.
4. Noninvasive treatment of cutaneous neurofibromas (cNFs): Results of a randomized prospective, direct comparison of four methods
5. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
6. CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS
7. NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
8. Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Anti-nerve Growth Factor (NGF) Antibody Tanezumab in Subjects with Moderate to Severe Pain Due to Schwannomatosis (P6-13.001)
9. Supplementary Table S3 from Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma
10. Supplementary Figure S1 from Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma
11. Investigating documentation of alcohol and non-medical substance use in oncology treatment: an electronic health record review
12. Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain
13. Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo
14. Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
15. Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]
16. Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRI
17. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.
18. Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma
19. Examining the effects of stress and psychological distress on smoking abstinence in cancer patients
20. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor
21. Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase–Positive Lung Cancer and CNS-Specific Relapse
22. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
23. Non-invasive Treatment of Cutaneous Neurofibromas (cNFs): Results of a Randomized Prospective, Direct Comparison of Four Methods
24. CTIM-39. A PHASE 1B STUDY OF PEMBROLIZUMAB, IBRUTINIB AND RITUXIMAB IN RECURRENT/REFRACTORY (RR) PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
25. CTNI-79. PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE ANTI-NERVE GROWTH FACTOR (NGF) ANTIBODY TANEZUMAB IN SUBJECTS WITH MODERATE TO SEVERE PAIN DUE TO SCHWANNOMATOSIS
26. 1040-E Deciphering and targeting the schwannoma-neuron-macrophage crosstalk for the treatment of schwannomatosis and associated pain
27. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors
28. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer
29. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
30. Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors
31. Temperature induced changes in the optical properties of skin in vivo
32. Septal bowing and pulmonary artery diameter on computed tomography pulmonary angiography are associated with short-term outcomes in patients with acute pulmonary embolism
33. Behavioral deficits, early gliosis, dysmyelination and synaptic dysfunction in a mouse model of mucolipidosis IV
34. Computed Tomography Imaging Characteristics of Non–Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis
35. Losartan rewires ovarian cancer tumor-immune microenvironment and suppresses IGF-1 to amplify chemo-immunotherapy sensitivity
36. Data from Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
37. Supplementary Data 1 from Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
38. Right‐to‐left ventricular ratio is higher in systole than diastole in patients with acute pulmonary embolism
39. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models
40. Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer
41. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma
42. Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
43. Barriers to participation in a prospective clinical trial for schwannomatosis-related pain (P7-13.003)
44. Prospective phase 2 trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2
45. Data from Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
46. Data from BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors
47. Interview with Dr. Engelman from BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors
48. Supplementary Figure Legends, Tables S1 - S3 from Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
49. Supplementary Figures 1-10, Tables 1-2 from BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors
50. Supplementary Figures S1 - S5 from Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.